loading...| Preferred Name | doxorubicin hydrochloride liposome | |
| Synonyms |
liposomal doxorubicin hydrochloride doxorubicin HCl liposome pegylated liposomal doxorubicin hydrochloride Pegylated Liposomal Doxorubicin liposomal doxorubicin TLC D-99 Stealth Liposomal Doxorubicin Doxorubicin Hydrochloride Liposomal (8S-cis)-8-acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-tri-hydroxy-1-methoxy-5,12-naphthacenedione Hydrochloride duomeisu doxorubicin hydrochloride liposome injection ATI-0918 Pegylated Liposomal Doxorubicin Hydrochloride liposome-encapsulated doxorubicin liposomal adriamycin Doxilen S-Liposomal Doxorubicin Caelyx pegylated doxorubicin HCl liposome Doxil |
|
| Definitions |
A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects; a liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1555" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1555" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000039424 |
|
| altLabel |
liposomal doxorubicin hydrochloride doxorubicin HCl liposome pegylated liposomal doxorubicin hydrochloride Pegylated Liposomal Doxorubicin liposomal doxorubicin TLC D-99 Stealth Liposomal Doxorubicin Doxorubicin Hydrochloride Liposomal (8S-cis)-8-acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-tri-hydroxy-1-methoxy-5,12-naphthacenedione Hydrochloride duomeisu doxorubicin hydrochloride liposome injection ATI-0918 Pegylated Liposomal Doxorubicin Hydrochloride liposome-encapsulated doxorubicin liposomal adriamycin Doxilen S-Liposomal Doxorubicin Caelyx pegylated doxorubicin HCl liposome Doxil |
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000037782 http://purl.bioontology.org/ontology/PDQ/CDR0000038301 http://purl.bioontology.org/ontology/PDQ/CDR0000258432 http://purl.bioontology.org/ontology/PDQ/CDR0000038232 http://purl.bioontology.org/ontology/PDQ/CDR0000042954 http://purl.bioontology.org/ontology/PDQ/CDR0000415354 http://purl.bioontology.org/ontology/PDQ/CDR0000037855 http://purl.bioontology.org/ontology/PDQ/CDR0000043066 http://purl.bioontology.org/ontology/PDQ/CDR0000438802 http://purl.bioontology.org/ontology/PDQ/CDR0000355720 http://purl.bioontology.org/ontology/PDQ/CDR0000043099 http://purl.bioontology.org/ontology/PDQ/CDR0000043078 http://purl.bioontology.org/ontology/PDQ/CDR0000038044 http://purl.bioontology.org/ontology/PDQ/CDR0000043062 http://purl.bioontology.org/ontology/PDQ/CDR0000042780 http://purl.bioontology.org/ontology/PDQ/CDR0000269351 http://purl.bioontology.org/ontology/PDQ/CDR0000038094 http://purl.bioontology.org/ontology/PDQ/CDR0000043088 http://purl.bioontology.org/ontology/PDQ/CDR0000371732 http://purl.bioontology.org/ontology/PDQ/CDR0000441230 http://purl.bioontology.org/ontology/PDQ/CDR0000038539 http://purl.bioontology.org/ontology/PDQ/CDR0000043110 http://purl.bioontology.org/ontology/PDQ/CDR0000037876 |
|
| cui |
C4287784 C1512061 C0701183 C0717726 C0701184 C1522690 C1522689 C4287823 C0279284 C1704361 |
|
| Date last modified |
2018-06-05 |
|
| definition |
A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects; a liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1555" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1555" NCI Thesaurus) |
|
| IND Code |
31919 |
|
| Legacy PDQ ID |
2059 |
|
| LT |
TRD |
|
| NCI ID |
C1555 |
|
| notation |
CDR0000039424 |
|
| NSC Code |
712227 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
doxorubicin hydrochloride liposome |
|
| tui |
T109 T195 T200 T121 |